HU-SGC @EC2611A

Analysts note Sinopharm Group's low P/E is no reason for excitement

Financial media analysis suggests Sinopharm is transforming from a traditional distributor to a health service ecosystem platform

Institutions focus on Sinopharm Group, believing policy will help the pharmacy industry reach a dual inflection point

Hang Seng Indexes Company announces quarterly review results; Sinopharm remains a constituent of the Hang Seng Composite Index

Sinopharm Group recognized by Gansu Provincial Government for its contribution to the province's medical and health industry

Sinopharm Holdings and Betta Pharmaceuticals reached a strategic cooperation

Sinopharm Group is estimated to have its annual ex-dividend date on June 16, 2026

A subsidiary of Sinopharm Group's application for generic Sacubitril Valsartan Sodium Tablets has been accepted

Sinopharm Group proposes to extend the commitment period for resolving horizontal competition with Taiji Group

HKEX to Temporarily Increase Margin Intervals for Sinopharm and Other Stock Options for Lunar New Year Holiday

The China International Medical Equipment Fair (CMEF), co-hosted by Sinopharm Group, will open in April

Multiple departments jointly issue the 'Implementation Plan for High-Quality Development of the Traditional Chinese Medicine Industry'

Sinopharm Group's subsidiary company's supplementary application for Amoxicillin and Clavulanate Potassium for Oral Suspension was accepted

Shanghai No. 1 Pharmacy Co., Ltd. expects to have RMB 35 million in daily operational related-party transactions with Sinopharm Group and its subsidiaries

Sinopharm Holding's Subsidiary Sinopharm Modern Has 51 Drugs Proposed for Selection in National Centralized Procurement Renewal

Sinopharm Group is expected to have its next ex-dividend date on June 17, 2026.

Southbound funds net sold HKD 110 million of Sinopharm Group on February 9

Zhitong Hong Kong Stock Connect Announces Statistics on Shareholding Ratio Changes

Sinopharm's subsidiary, Taiji Group, to hold its first extraordinary general meeting of 2026

Sinopharm Holdings Held its 2026 Annual Work Conference to Deploy Key Tasks for the New Year

STARCOIN GROUP

AE LOGISTICS

GUANZE MEDICAL

WATER INDUSTRY

ZHONGSHI MINAN

IDT INT'L

HAIZHI TECH GP

MANY IDEA CLOUD

FIRST CAP GP

XL2CSOPCOIN-U

600511

516500

516820

01099

512010

Sinopharm Group Co. Ltd. (HKG:1099) has a low P/E ratio of 8.4x, indicating potential investor caution due to declining earnings. The company's EPS fell by 14% last year and 11% over three years, leading to a forecasted growth of only 14% next year, below the market's 20%. This suggests that investors are not optimistic about future earnings, resulting in a low P/E. Analysts believe the share price may not rise significantly in the near future, and there is one warning sign to consider before investing.

Simplywall

SINOPHARM(CNCM LTD)

ChinaAMC CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Guotai SSE STAR Brand Name Drug ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

China Merchants CSI Biotechnology Theme ETF

Penghua CSI HK Connect Health Care Composite ETF

Sinopharm Accord

SINOPHARM

ICBCCS SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

Minsheng Royal CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Universal 800 Health Care ETF

E Fund Hang Seng SCHK Innovative Drug ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Guotai CSI Bio-medicine ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Bosera Hang Seng Health Care ETF(QDII)

Tianhong CNI BIOMEDICINE ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Sinopharm Group Co. Ltd.'s (HKG:1099) Low P/E No Reason For Excitement

03320

Beijing launched a pilot program for online diagnosis and treatment services on January 31, starting with three pediatric subspecialties at Beijing Children's Hospital and Capital Institute of Pediatrics. This service provides online pre-consultation, online diagnosis and treatment, and medication delivery for first-time patients, aiming to ensure the safety and quality of diagnosis and treatment. Doctors can complete the initial diagnosis and issue prescriptions via the internet

Wallstreetcn

CHINARES PHARMA

ChinaAMC CSI All Share Health Care Devices ETF

Shanghai Pharma

China Merchants CSI All Share Medical Apparatus and Instruments ETF

ALI HEALTH

JD HEALTH

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

PA GOODDOCTOR

Founder Fubon CSI Medicine and Medical Device Innovation ETF

GF CSI All Share Health Care ETF

SH PHARMA

Dacheng CSI All Share Health Care Equipment and Services ETF

This afternoon, appointment reservations opened for the pilot program of internet diagnosis and treatment in Beijing

Sinopharm Group Co. Ltd. has filed an updated list of directors with the Hong Kong Stock Exchange, detailing their roles and committee memberships. The board includes Non-Executive, Executive, and Independent Non-Executive Directors, with Jin Bin as Chairman. The filing reflects a broad distribution of responsibilities across governance, strategy, compliance, remuneration, and nomination functions. This information was published by Sinopharm Group via the Hong Kong Stock Exchange's Issuer Information Service.

Reuters

Sinopharm Group Files Director List with HKEX

Sinopharm Group's renewed distribution partnership with Shanghai Henlius Biotech extends their collaboration until 2028. Despite a modest recent share price increase, Sinopharm's long-term returns remain strong. The company's current price-to-earnings ratio of 8.1x suggests undervaluation compared to industry averages. However, a DCF model indicates a fair value of HK$15.36, suggesting potential overvaluation. Risks include policy changes and slower procurement growth. Investors are encouraged to explore further investment opportunities and assess potential mispricing in the market.

Sinopharm Group (SEHK:1099): Valuation Check After Renewing Shanghai Henlius Distribution Partnership

Sinopharm Group Co. Ltd. will hold an extraordinary general meeting on December 19, 2025, in Shanghai, China. Shareholders will vote on appointing Mr. Jin Bin and Ms. Li Ying as non-executive Directors of the Board, with authorization for the Board to determine their remuneration and service contracts. This announcement was published by Sinopharm Group via the Hong Kong Stock Exchange's Issuer Information Service.

Sinopharm Group Co. Ltd. Announces Date for Extraordinary General Meeting

02696

Shanghai Henlius Biotech Inc. has renewed its distribution agreement with Sinopharm Group, signing a new framework on December 3, 2025. This extends their partnership, with transactions conducted in the ordinary course of business. An Independent Board Committee will advise shareholders on the agreement's fairness. The news was generated by Public Technologies using AI and is for informational purposes only.

HENLIUS

Shanghai Henlius Biotech Renews Distribution Agreement with Sinopharm

SINOPHARM announced that due to work arrangements, Zhao Bingxiang has resigned from his positions as non-executive director and chairman of the board on November 28. The board has resolved to elect Jin Bin as the chairman and authorized representative, and on the same day appointed Jin Bin and Li Ying as non-executive directors

AASTOCKS

SINOPHARM appoints chairman

Sinopharm Group Co. Ltd. announced the resignations of Mr. Zhao Bingxiang and Ms. Feng Rongli from various board and committee positions, effective upon their replacements' appointment at the company's general meeting.

marketscreener

Sinopharm Group Co. Ltd. Announces Board and Committee Resignations

Sinopharm Group Co. Ltd. announced the resignation of Mr. Zhao Bingxiang as non-executive director, chairman of the board, and authorized representative due to work arrangements. The company will provide details on new director appointments in a future circular to shareholders. This announcement was made via the Hong Kong Stock Exchange's Issuer Information Service.

Sinopharm Chairman Zhao Bingxiang Resigns Amid Board Reshuffle

JPMorgan Chase & Co's short position in H-shares of Sinopharm Group decreased to 1.45% on Nov 21 - HKEX

JPMorgan Chase

JPMorgan Chase & Co's short position in H-shares of Sinopharm Group decreased to 1.45% on Nov 21 - HKEX

Investing in Sinopharm Group (HKG:1099) three years ago would have delivered a 34% total shareholder return, largely due to dividends, despite a modest 19% share price increase. The company's earnings per share dropped 3.7% annually, and revenue growth was only 1.1%. The CEO's pay is below the median for similar-sized companies. Analysts predict future profit estimates, and investors should consider market conditions and investment risks.

Investing in Sinopharm Group (HKG:1099) three years ago would have delivered you a 34% gain

HU-SGC @EC2611A(21718.HK)

Sinopharm Group Co. Ltd.'s (HKG:1099) Low P/E No Reason For Excitement

This afternoon, appointment reservations opened for the pilot program of internet diagnosis and treatment in Beijing

Sinopharm Group Files Director List with HKEX

Sinopharm Group (SEHK:1099): Valuation Check After Renewing Shanghai Henlius Distribution Partnership

Sinopharm Group Co. Ltd. Announces Date for Extraordinary General Meeting